#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	13148	16S	1529	1529	99.93	16S.l15.c30.ctg.1	2131	613.2	0	.	n	.	0	C1450T	SNP	1450	1450	C	1665	1665	T	739	T	664	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	13148	16S	1529	1529	99.93	16S.l15.c30.ctg.1	2131	613.2	1	SNP	n	C1184T	0	.	.	1184	1184	C	1399	1399	C	784	C	707	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24046	23S	2890	2890	99.9	23S.l6.c30.ctg.1	3622	662.1	0	.	n	.	0	A9G	SNP	9	9	A	380	380	G	686	G,A	608,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24046	23S	2890	2890	99.9	23S.l6.c30.ctg.1	3622	662.1	0	.	n	.	0	T695C	SNP	695	695	T	1066	1066	C	728	C,T	664,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24046	23S	2890	2890	99.9	23S.l6.c30.ctg.1	3622	662.1	0	.	n	.	0	T1971C	SNP	1971	1971	T	2342	2342	C	754	C	684	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24046	23S	2890	2890	99.9	23S.l6.c30.ctg.1	3622	662.1	1	SNP	n	A2045G	0	.	.	2045	2045	A	2416	2416	A	734	A	688	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24046	23S	2890	2890	99.9	23S.l6.c30.ctg.1	3622	662.1	1	SNP	n	C2597T	0	.	.	2597	2597	C	2968	2968	C	749	C,T	695,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	1832	folP	855	855	99.77	folP.l15.c4.ctg.1	1379	131.6	1	SNP	p	R229S	1	.	.	685	687	AGC	911	913	AGC	183;184;186	A,C;G;C	167,1;170;170	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	4892	gyrA	2751	2751	99.78	gyrA.l15.c4.ctg.1	3349	145.6	0	.	p	.	0	T243I	NONSYN	727	729	ACA	1071	1073	ATA	137;134;133	A;T;A	126;125;122	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	4892	gyrA	2751	2751	99.78	gyrA.l15.c4.ctg.1	3349	145.6	0	.	p	.	0	M250I	NONSYN	748	750	ATG	1092	1094	ATA	138;138;140	A;T;A	124;124;127	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	4892	gyrA	2751	2751	99.78	gyrA.l15.c4.ctg.1	3349	145.6	1	SNP	p	S91F	0	.	.	271	273	TCC	615	617	TCC	163;162;166	T;C;C	148;146;150	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	4892	gyrA	2751	2751	99.78	gyrA.l15.c4.ctg.1	3349	145.6	1	SNP	p	D95N	0	.	.	283	285	GAC	627	629	GAC	162;163;161	G;A;C	150;149;149	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	4892	gyrA	2751	2751	99.78	gyrA.l15.c4.ctg.1	3349	145.6	1	SNP	p	D95G	0	.	.	283	285	GAC	627	629	GAC	162;163;161	G;A;C	150;149;149	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_F_01564	mtrR.WHO_F_01564	1	1	27	1636	mtrR	633	633	100.0	mtrR.l15.c30.ctg.1	1233	131.8	1	SNP	p	G45D	0	.	.	133	135	GGC	432	434	GGC	214;214;218	G;G;C	198;199;200	mtrR.WHO_F_01564:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	796	mtrR_promoter	250	250	99.6	mtrR_promoter.l6.c17.ctg.1	950	83.5	0	.	n	.	0	.206T	INS	206	206	T	619	619	T	198	T	181	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4392	parC	2304	2304	99.74	parC.l15.c17.ctg.1	2925	149.6	0	.	p	.	0	V421A	NONSYN	1261	1263	GTC	1581	1583	GCC	173;171;173	G;C;C	158;160;160	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4392	parC	2304	2304	99.74	parC.l15.c17.ctg.1	2925	149.6	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1623	1625	GCA	166;168;166	G;C;A	147;142;143	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4392	parC	2304	2304	99.74	parC.l15.c17.ctg.1	2925	149.6	1	SNP	p	D86N	0	.	.	256	258	GAC	576	578	GAC	179;178;178	G;A;C	163;162;163	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4392	parC	2304	2304	99.74	parC.l15.c17.ctg.1	2925	149.6	1	SNP	p	S87W	0	.	.	259	261	AGT	579	581	AGT	174;174;175	A;G;T	159;160;160	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4392	parC	2304	2304	99.74	parC.l15.c17.ctg.1	2925	149.6	1	SNP	p	S87I	0	.	.	259	261	AGT	579	581	AGT	174;174;175	A;G;T	159;160;160	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4392	parC	2304	2304	99.74	parC.l15.c17.ctg.1	2925	149.6	1	SNP	p	S87R	0	.	.	259	261	AGT	579	581	AGT	174;174;175	A;G;T	159;160;160	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4392	parC	2304	2304	99.74	parC.l15.c17.ctg.1	2925	149.6	1	SNP	p	S88P	0	.	.	262	264	TCC	582	584	TCC	174;171;173	T;C;C	155;158;157	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_W_01411c	parE.WHO_W_01411c	1	1	27	4086	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2505	162.3	1	SNP	p	G410V	0	.	.	1228	1230	GGT	1476	1478	GGT	211;210;207	G;G;T	188;188;177	parE.WHO_W_01411c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.22.001	penA.22.001	1	1	27	3840	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2334	163.7	1	SNP	p	A311V	0	.	.	931	933	GCA	1198	1200	GCA	210;213;211	G;C,G;A	189;191,1;193	penA.22.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3840	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2334	163.7	1	SNP	p	I312M	0	.	.	934	936	ATC	1201	1203	ATC	210;209;217	A;T;C,A	193;191;198,1	penA.22.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3840	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2334	163.7	1	SNP	p	V316P	0	.	.	946	948	GTG	1213	1215	GTG	217;216;219	G;T;G	201;197;205	penA.22.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3840	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2334	163.7	1	SNP	p	V316T	0	.	.	946	948	GTG	1213	1215	GTG	217;216;219	G;T;G	201;197;205	penA.22.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3840	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2334	163.7	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1717	1719	ACC	214;215;215	A;C;C	182;194;196	penA.22.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3840	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2334	163.7	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1771	1773	GCG	218;216;218	G;C;G	193;181;183	penA.22.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3840	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2334	163.7	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1771	1773	GCG	218;216;218	G;C;G	193;181;183	penA.22.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3840	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2334	163.7	1	SNP	p	G543S	0	.	.	1627	1629	GGT	1894	1896	GGT	190;189;192	G;G;T	166;169;168	penA.22.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3840	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2334	163.7	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1903	1905	GGC	188;185;187	G;G;C	166;163;163	penA.22.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3840	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2334	163.7	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1921	1923	CCG	183;185;189	C,G;C;G	125,1;150;141	penA.22.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5140	ponA	2397	2397	99.96	ponA.l15.c30.ctg.1	3083	166.1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2172	porA	1146	1146	99.65	porA.l15.c4.ctg.1	1876	115.3	0	.	p	.	0	S22G	NONSYN	64	66	AGC	426	428	GGC	148;146;145	G;G;C	139;138;138	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2172	porA	1146	1146	99.65	porA.l15.c4.ctg.1	1876	115.3	0	.	p	.	0	M83fs	FSHIFT	247	247	A	608	608	C	163	C	149	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2424	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	1592	151.4	0	.	p	.	0	T18M	NONSYN	52	54	ACG	455	457	ATG	214;213;212	A;T,C;G	197;195,1;195	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2424	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	1592	151.4	0	.	p	.	0	E48R	NONSYN	142	144	GAA	545	547	AGA	170;171;170	A,G;G;A	158,1;160;160	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2424	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	1592	151.4	0	.	p	.	0	V75I	NONSYN	223	225	GTT	626	628	ATT	184;186;187	A;T;T	174;172;173	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2424	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	1592	151.4	0	.	p	.	0	T89S	NONSYN	265	267	ACC	668	670	AGC	202;203;203	A;G;C	190;187;187	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2424	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	1592	151.4	0	.	p	.	0	V98I	NONSYN	292	294	GTC	695	697	ATC	181;184;185	A;T;C	168;166;169	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2424	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	1592	151.4	0	.	p	.	0	.	MULTIPLE	358	359	AA	760	761	CG	199;199	C;G	185;180	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2424	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	1592	151.4	0	.	p	.	0	.	MULTIPLE	361	362	GA	763	765	CAG	197;195;196	C;A;G	181;184;183	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2424	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	1592	151.4	0	.	p	.	0	N122K	NONSYN	364	366	AAC	767	769	AAA	191;192;191	A;A;A	181;181;180	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2424	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	1592	151.4	0	.	p	.	0	F131Y	NONSYN	391	393	TTT	794	796	TAT	208;210;208	T;A;T	193;196;195	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2424	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	1592	151.4	0	.	p	.	0	N134E	NONSYN	400	402	AAT	803	805	GAG	199;196;196	G;A;G	190;188;187	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2424	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	1592	151.4	0	.	p	.	0	V135F	NONSYN	403	405	GTG	806	808	TTT	197;198;198	T;T;T	176;185;190	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2424	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	1592	151.4	0	.	p	.	0	G140K	NONSYN	418	420	GGA	821	823	AAA	191;191;190	A;A;A	181;182;181	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2424	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	1592	151.4	0	.	p	.	0	K143E	NONSYN	427	429	AAA	830	832	GAA	186;185;185	G;A;A	175;171;176	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2424	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	1592	151.4	0	.	p	.	0	V151A	NONSYN	451	453	GTA	854	856	GCA	191;191;192	G;C;A	176;171;173	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2424	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	1592	151.4	0	.	p	.	0	G211R	NONSYN	631	633	GGA	1034	1036	AGA	214;215;216	A;G;A	199;197;199	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2424	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	1592	151.4	0	.	p	.	0	T213S	NONSYN	637	639	ACA	1040	1042	TCA	226;226;224	T;C;A	205;206;207	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2424	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	1592	151.4	0	.	p	.	0	G253Q	NONSYN	757	759	GGA	1160	1162	CAA	180;177;174	C;A;A	167;166;165	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2424	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	1592	151.4	0	.	p	.	0	.	INDELS	760	762	ACA	1164	1168	ATCAA	174;171;172;168;166	A;T;C;A;A	165;162;166;162;162	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2424	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	1592	151.4	0	.	p	.	0	.	INDELS	763	764	TG	1171	1173	AGT	166;165;164	A;G;T	160;159;159	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2424	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	1592	151.4	0	.	p	.	0	A257D	NONSYN	769	771	GCT	1178	1180	GAT	170;169;167	G;A;T	164;162;162	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2424	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	1592	151.4	0	.	p	.	0	T269S	NONSYN	805	807	ACC	1214	1216	AGC	181;183;180	A;G,C;C	170;170,1;167	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2424	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	1592	151.4	0	.	p	.	0	D293S	NONSYN	877	879	GAT	1286	1288	AGT	219;218;217	A;G;T	196;195;192	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2424	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	1592	151.4	0	.	p	.	0	N295D	NONSYN	883	885	AAC	1292	1294	GAC	215;217;216	G;A;C	196;196;197	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2424	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	1592	151.4	0	.	p	.	0	H296Y	NONSYN	886	888	CAC	1295	1297	TAC	217;216;219	T;A;C	199;198;202	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2424	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	1592	151.4	1	SNP	p	G120K	1	.	.	358	360	AAG	760	762	CGG	199;199;197	C;G;G	185;180;179	porB1b.WHO_M_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2424	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	1592	151.4	1	SNP	p	A121D	1	.	.	361	363	GAC	763	766	CGC	197;196;194	C;G;C	181;183;182	porB1b.WHO_M_02204c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2424	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	1592	151.4	1	SNP	p	D121N	0	.	.	361	363	GAC	763	766	CGC	197;196;194	C;G;C	181;183;182	porB1b.WHO_M_02204c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	9644	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	4932	194.9	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2006	2008	CAT	192;192;192	C;A;T	181;181;181	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1086	rpsJ	312	312	100.0	rpsJ.l15.c30.ctg.1	1073	100.7	1	SNP	p	V57M	1	.	.	169	171	ATG	489	491	ATG	230;236;234	A;T;G	213;219;217	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
